FINWIRES · TerminalLIVE
FINWIRES

Star Sports Medicine Nets HK$758 Million Ahead of Hong Kong Trading Debut

By

Star Sports Medicine (HKG:1609) raised HK$758.4 million in net proceeds from its initial public offering in Hong Kong.

The offer price was set at HK$98.50 per H-share, according to a Monday filing with the Hong Kong Stock Exchange.

The China-based medical device company offered 8.4 million H-shares in the global offering.

The Hong Kong public offer was 7,823.13 times subscribed, with a final allocation of 842,200 shares, representing 10% of the total offering.

The international offering was 10.41 times subscribed, with a final allocation of 7.6 million shares, or 90% of the total offering.

Cornerstone investors, including JSC International Investment Fund SPC, OAP IV (HK) Limited, and Greater Bay Area Development Fund Management, were allocated about 2.9 million shares in the international tranche, according to the filing.

Star Sports Medicine is scheduled to debut on the Hong Kong bourse on Tuesday, May 5.

Related Articles

Asia

Atul Auto's Sales Rise 74% in April

Three-wheeler manufacturer Atul Auto's (NSE:ATULAUTO, BOM:531795) total sales jumped 74% to 3,001 units in April from 1,725 units sold a year ago, according to a Friday filing to the Indian stock exchanges.Of the total, domestic sales grew sharply year-on-year to 2,478 units in April from 1,427 units.

BOM:531795NSE:ATULAUTO
Asia

Leader Education's Fiscal H1 Profit Falls 17%

Leader Education (HKG:1449) booked 20.2 million yuan in attributable profit for the fiscal first half ended Feb. 28, down 17% from 24.2 million yuan a year earlier, according to a Hong Kong bourse filing Sunday.The higher education services company's shares fell nearly 2% in morning trade Monday.Earnings per share were 0.0303 yuan, compared with 0.0363 yuan in the prior-year period.Revenue rose 11% year on year to 191.3 million yuan, figures showed.

HKG:1449
Asia

Market Chatter: CSL, Resmed, Cochlear Lead Losses on ASX

CSL (ASX:CSL) led losses on the Australian bourse so far this year at AU$23.2 billion, while ResMed (ASX:RMD) and Cochlear (ASX:COH) followed with losses of AU$10.6 billion, the Australian Financial Review reported Monday, citing Global X ETFs.Negative performing companies on the S&P/ASX 200 index collectively wiped out over AU$217 billion, said Marc Jocum, senior product and investment strategist at Global X ETFs.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

ASX:COHASX:CSLASX:RMD